Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study.

@article{Humpl2005BeneficialEO,
  title={Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study.},
  author={Tilman Humpl and Janette T. Reyes and Helen H K Holtby and Derek Stephens and Ian Adatia},
  journal={Circulation},
  year={2005},
  volume={111 24},
  pages={3274-80}
}
BACKGROUND Pulmonary arterial hypertension (PAH) is a progressive and fatal disease. Sildenafil is a type 5 phosphodiesterase inhibitor and pulmonary vasodilator. Therefore, we hypothesized that sildenafil would improve distance walked in 6 minutes and hemodynamics in children with PAH. METHODS AND RESULTS After baseline assessment of hemodynamics by… CONTINUE READING